SHARx: TrumpRx platform exposes issues in drug pricing and access
SHARx argues that without tackling rebate-driven economics and PBM decision-making power, efforts to lower drug prices may have limited impact on patients.
SHARx
As 2026 Rx price hikes begin, SHARx targets the specialty drug 鈥淏lack Box鈥�
As drugmakers implement 2026 price increases, SHARx argues that specialty pharmacy practices, not just list prices, often determine patient access and out-of-pocket costs.